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Abstract
Hypertrophic cardiomyopathy occurs as an autosomal domi-
nant familial disorder or as a sporadic disease without familial
involvement. While missense mutations in the ft cardiac myosin
heavy chain (MHC) gene account for approximately half of all
cases of familial hypertrophic cardiomyopathy, the molecular
causes of sporadic hypertrophic cardiomyopathy are unknown.
To determine whether ft cardiacMHC mutations are also asso-
ciated with sporadic disease, we screened this gene in seven
individuals with sporadic hypertrophic cardiomyopathy. Muta-
tions in the ft cardiac MHC genes were identified in two pro-
bands with sporadic disease. In that their parents were neither
clinically nor genetically affected, we conclude that mutations
in each proband arose de novo. Transmission of the mutation
and disease to an offspring occurred in one pedigree, predicting
that these are germline mutations. The demonstration ofhyper-
trophic cardiomyopathy arising within a pedigree coincident
with the appearance of a de novo mutation provides compelling
genetic evidence that ft cardiac MHC mutations cause this dis-
ease. We suggest that de novo mutations account for some in-
stances of sporadic hypertrophic cardiomyopathy and that
these mutations can be transmitted to children. The clinical
benefits of defining mutations responsible for familial hyper-
trophic cardiomyopathy should also be available to some pa-
tients with sporadic disease. (J. Clin. Invest. 1992. 90:1666-
1671.) Key words: cardiac hypertrophy * myosin heavy chain
gene - RNase protection
Introduction
Hypertrophic cardiomyopathy is defined as a primary myocar-
dial disorder (1, 2), characterized by increased ventricular
mass with myocyte and myofibrillar disarray (3, 4), that occurs
in the absence of other cardiac or systemic disorders. The diag-
nosis of hypertrophic cardiomyopathy is based upon the dem-
onstration of unexplained ventricular hypertrophy. Hyper-
trophy is typically asymmetric, involving the septum and left
ventricular free wall (5-7), but may be concentric or confined
to the distal left ventricle and/or right ventricle (8-10). The
familial form of hypertrophic cardiomyopathy is inherited as
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an autosomal dominant trait (5, 11-14). Thus, individuals
with familial hypertrophic cardiomyopathy frequently have
multiple affected relatives, and must have one affected parent.
Sporadic occurrence of hypertrophic cardiomyopathy is de-
fined by similar anatomical and clinical features in an individ-
ual whose parents do not have the condition (6, 15).
Estimation ofthe fraction ofhypertrophic cardiomyopathy
that occurs as sporadic disease has been difficult. Two studies
using two-dimensional echocardiography in families of pro-
bands with at least three available first degree relatives sug-
gested that hypertrophic cardiomyopathy was sporadic in 44%
( 16) and 33% (17). However, clinical studies tend to overesti-
mate the proportion of sporadic disease for several reasons.
First, the severity and distribution of hypertrophy vary consid-
erably, even between related family members, hence assign-
ment of disease status may be inaccurate. Second, there are
difficulties ofascertainment in retrospective studies where fam-
ily members, especially parents, may be deceased or unavail-
able for study. Third, many ofthe families studied are too small
for familial disease to manifest. For these reasons affected rela-
tives may not be identified, with the result that the disease is
assumed to be sporadic.
We have previously identified j3 cardiac myosin heavy
chain (MHC)' mutations that cause familial hypertrophic car-
diomyopathy in about 50% of unrelated families with this dis-
order ( 18-21 ). Seven different mutations have been identified;
all are missense mutations affecting conserved residues in the
amino-terminal half of the myosin heavy chain. Knowledge of
the particular 3 cardiac MHC gene mutation in a family with
hypertrophic cardiomyopathy is of clinical importance, in
terms of both diagnosis (20) and prognosis (21 ).
To investigate the molecular basis ofsporadic hypertrophic
cardiomyopathy we screened the ,3 cardiac MHC genes of
seven unrelated probands with sporadic hypertrophic cardio-
myopathy. Diagnosis was based on the presence oftypical clin-
ical features of the disease in the proband and the absence of
disease criteria in both parents. We demonstrate that two of
these probands have /3 cardiacMHC mutations that are compa-
rable to those found in patients with familial hypertrophic car-
diomyopathy. Genetic analyses ofthe probands' parents reveal
that both mutations have arisen de novo, coincident with the
appearance of hypertrophic cardiomyopathy.
Methods
Clinical evaluation. After informed consent was obtained in accor-
dance with the Brigham and Women's Hospital Committee for the
1. Abbreviations used in this paper: MHC, myosin heavy chain; STR,
short tandem repeat (sequence).
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Protection ofHuman Subjects from Research Risks, blood was drawn
from probands and their first-degree relatives. Clinical, electrocardio-
graphic, and echocardiographic assessments were performed as de-
scribed previously (22). The diagnosis of hypertrophic cardiomyopa-
thy was based on the demonstration ofunexplained left, right or biven-
tricular hypertrophy. An individual was diagnosed with sporadic
disease if both parents were available for study and lacked criteria for
diagnosis of hypertrophic cardiomyopathy.
Detection ofmutations. The techniques used to screen the ft cardiac
MHC gene coding sequence for mutations have been described in de-
tail elsewhere (20, 21 ). The polymerase chain reaction (PCR) was used
to amplify # cardiac MHC gene or mRNA sequences from affected
individuals' Epstein-Barr virus transformed lymphocytes. Both normal
and mutationally altered ft cardiac MHC mRNA was detected by two
rounds ofPCR amplification. Amplified sequences were hybridized to
RNA probes transcribed from a normal gene and RNase A protection
assays performed as described previously (20, 21 ). The entire # cardiac
MHC coding sequence was examined in all probands, using both sense
and antisense riboprobes.
Amplified DNAs that yielded abnormal RNase cleavage patterns
were reanalyzed with new DNA isolates to exclude artifacts arising
from PCR, and then subjected to dideoxy nucleotide sequence analy-
sis. Where possible, the nucleotide change identified by sequencing was
independently confirmed by demonstration of a predicted change in
restriction enzyme site. Amino acid sequences were deduced from
DNA sequences.
Genetic analysis offamilies. When a mutation was identified in a
proband with sporadic hypertrophic cardiomyopathy its presence was
sought in first-degree relatives by either RNase protection assays or
restriction enzyme digestion. Paternity was confirmed by demonstra-
tion of inheritance of appropriate alleles at eight polymorphic dimeric
short tandem repeat sequences (STRs): APOAII, APOCII, ASS,
DIS103, DlSl 16, GCG, INT2, and PLA2 (23-29), using PCR condi-
tions as described previously with end-labeled forward primers (23).
Allele frequencies were calculated from a panel of 22 unrelated pro-
bands. The parental origin and subsequent inheritance of chromo-
somes bearing the de novo mutations in the probands was assessed by
analysis ofinheritance ofalleles at polymorphisms within the # cardiac
MHC gene: dimeric STRs in the 5' untranslated region (30) and in
intron 24 (31 ) and the restriction fragment length polymorphism iden-
tified by probe pSC14 (32).
Results
Seven unrelated probands with sporadic hypertrophic cardio-
myopathy were identified; all had typical features of hypertro-
phic cardiomyopathy with maximum left ventricular wall
thickness ranging from 1.8 to 4.0 cm (median 3.0 cm). The ,3
cardiac MHC gene was analyzed in each proband, using the
RNase protection assay. ,3 cardiac MHC gene mutations were
found in two of these probands, designated H and AR.
Clinical analyses
Family H. Individual 11-2 in family H was diagnosed with hy-
pertrophic cardiomyopathy because of typical clinical features
(Table I and Fig. 1 ). The proband's father (I-1 ) has a 10-year
history of treatment for essential hypertension and symptom-
atic ischemic heart disease and underwent open heart surgery
in 1974 for excision ofa left atrial myxoma. A 12-lead electro-
cardiogram showed atrial flutter with minor repolarization
changes; a two-dimensional echocardiogram demonstrated a
dilated left atrium (6 cm) and a mildly dilated poorly contract-
ing left ventricle without hypertrophy. Based on the absence of
typical features of hypertrophic cardiomyopathy, and the pres-
ence of known cardiovascular disease, individual I-1 was diag-
nosed as unaffected by hypertrophic cardiomyopathy. Clinical
analyses of the proband's mother (1-2) were entirely normal.
Individuals 1-1 and 1-2 had not been studied previously. Pre-
vious analyses of the proband's children had identified one
affected individual, III-2 (21 ). All other members ofthe family
have an entirely normal clinical examination, EKG and echo-
cardiogram.
Family AR. Individual 11-1 in family AR also has typical
clinical features ofhypertrophic cardiomyopathy, with marked
asymmetric septal hypertrophy and systolic anterior motion of
the mitral valve (Table I). The proband's father, individual I- 1,
had a past medical history of myocardial infarction in 1979. A
12-lead electrocardiogram showed anteroseptal Q waves; there
were no features of hypertrophic cardiomyopathy on two-di-
mensional echocardiogram. Clinical studies of all other first
Table I. Clinical Features ofAffected Individuals and Their Parents in Families H andAR
Clinical symptoms Electrocardiogram* 2-D echocardiogramt
Subject Age/Sex Chest pain Dyspnea Syncope BBB ABN Q LVH +/-ST MAX LVWT RVH SAM LA SIZE
mm mm
HI-If 73M + I - - - - 14 - - 60
HI-2 70F - I - - - - 9 - - 32
H II-2 44F + III - L - - 18 - - 50
H III-2 24 F - II - - + + 28 + ++ 42
AR I-l"1 70 M - I - - + 11 - - 30
AR I-2 63 F - I - - - - 10 - - 40
ARII-1 40F + I + - - + 38 - + 38
* Electrocardiographic abnormalities included bundle branch block (BBB; L, left), abnormal Q waves (ABN Q), and left ventricular hypertrophy
with or without associated ST changes (LVH +/- ST).
$ Echocardiographic findings included maximum left ventricular wall thickness (MAX LVWT), right ventricular hypertrophy (RVH), systolic
anterior motion of the mitral valve (SAM; + incomplete, ++ complete), and left atrial size (LA SIZE).
9Electrocardiogram showed atrial flutter with repolarization changes (see text).
"Electrocardiogram showed anteroseptal Q waves due to previous myocardial infarction.
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Figure 1. Echocardiograms of
members of family H. Short-axis 2-
D echocardiogram views taken at
the level of the mitral valve leaflets
are shown with a schematic illus-
trating the anatomical structures vi-
sualized (LV, left ventricle; MV,
mitral valve; IVS, interventricular
septum; RV, right ventricle). LV
wall thickness is normal in individ-
uals I- 1, I-2, and II-1 and abnormal
in individuals 11-2 and III-2.
degree relatives, including the proband's mother and children,
were entirely normal.
Genetic analyses
Family H. A f3 cardiac myosin heavy chain gene mutation in
the proband of family H was detected previously (21 ). This G
to A transition in exon 23 (designated Glu924Lys) encodes a
lysine residue rather than a glutamic acid residue at position
924 (numbered according to reference 30). The nucleotide
substitution, as detected by an RNase protection assay ofDNA
amplified from exon 23 (Fig. 2), is present in both the proband
(II-2) and her daughter (III-2), but neither parent. This result
was confirmed by repeat analysis ofindependent samples from
each family member. This mutation does not result in any
change in restriction enzyme site.
Two possible explanations exist for the finding that neither
parent bears the mutation present in the proband. Either the
mutation has arisen de novo, or else has been inherited from a
father other than individual I- 1. To determine if individual I-1
was the biological father of individuals 11-1 and II-2 we have
characterized the alleles found in father (I-I), mother (1-2),
son (II-1), and daughter (II-2) at eight polymorphic STRs
spread throughout the genome (Methods). At each locus the
children have inherited alleles present in the father's genome,
rather than other alleles that exist in the general population
(Fig. 3 and data not shown). From the frequency of the in-
herited alleles in the population we have calculated that the
odds that a particular individual, chosen at random from the
population, would have been able to produce the alleles found
in individuals II-I or II-2 are < 1 in 100,000. We conclude that
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243 bp
152 bp
abnormality on RNase protection. Nucleotide sequence analy-
sis revealed this to be due to a C to T transition in exon 20
(affecting nucleotide residue 2253, numbered according to ref-
erence 33). This substitution encodes a change from the nor-
mal arginine amino acid residue to a cysteine in the mutant
polypeptide, and is designated Arg723Cys. Arginine residue
723 is conserved among all known cardiac MHC's and all ver-
tebrate striated muscle MHC's except the human perinatal and
rabbit skeletal isoforms (34); mutation to a cysteine residue
constitutes a nonconservative substitution with a change in net
charge. This missense mutation, which is highly analogous to
those others previously described, has not been seen in analyses
of more than 180 normal chromosomes.
The nucleotide substitution involved in the Arg723Cys
mutation is predicted to abolish a BcgI restriction enzyme site
present in the normal cDNA sequence. Digestion of amplified
cDNA sequences with this enzyme (Fig. 4) confirms the pres-
ence of the mutation in individual II- 1 and also confirms that
all other members ofthe family are genetically unaffected. The
paternal relationship of individual 1-1 to 11-1 was confirmed
with the eight polymorphic markers, providing odds ofgreater
than 100,000 to 1 in favor of paternity. The , cardiac MHC
gene polymorphisms were not sufficiently informative in fam-
ily AR to determine the parental origin of the chromosome
that acquired the Arg723Cys mutation.
91 bp -*o IW '0
Figure 2. Detection of the Glu924Lys mutation in exon 23 in
members of family H by RNase protection assay. The pedigree is
shown above. Squares denote males and circles denote females; solid
symbols denote those clinically affected and open symbols denote
those unaffected. Below is an RNase protection assay ofexon 23 DNA
from each individual, in corresponding positions to those of the ped-
igree. Amplified DNA is hybridized to a 32P-labeled RNA probe of
normal ,B MHC sequence which is then digested with RNase A, re-
sulting in cleavage at mismatched bases. The normal exon protects
a 243 base fragment (arrow); the Glu924Lys mutation results in
cleavage of this to fragments of 91 and 152 bases (arrows). Cleavage
due to the nucleotide mismatch is present only in the clinically af-
fected individuals 11-2 and III-2.
individual I-1 is the biological father of both the proband and
her unaffected brother.
The parental origin ofthe chromosome bearing the de novo
mutation was assessed by haplotype analysis of the 13 cardiac
MHC gene. Polymorphisms in a dimeric STR present in the 5'
untranslated region (methods) demonstrate that the chromo-
some bearing the Glu924Lys mutation in the proband (II-2)
was inherited from the father (I- I). This chromosome, which
bears a normal copy ofthe 13 cardiac MHC gene in the father, is
also inherited in its normal state by an unaffected son (II-1)
(data not shown). Thus this normal chromosome is associated
with absence of hypertrophic cardiomyopathy in individuals
I-1 and II- 1, but once carrying the new Glu924Lys mutation is
associated with the appearance of hypertrophic cardiomyopa-
thy in individuals II-2 and 111-2.
Family AR. Screening the 13 cardiac MHC gene cDNA se-
quence in the proband of family AR (11-1) identified a novel
Discussion
These analyses identify two examples of missense mutations in
the : cardiac MHC genes of individuals with hypertrophic car-
diomyopathy whose parents are clinically and genetically unaf-
fected. We speculate that the 1 cardiac MHC gene mutations in
both probands arose in a germline cell as these mutations are
expressed in cells ofdifferent lineages, including myocytes and
peripheral leukocytes, as well as ovarian germ cells in the pro-
band of family H. Collectively, these data suggest that sporadic
hypertrophic cardiomyopathy can result from new mutations
that may then be inherited. In one family studied (AR), the
affected proband is typical of cases of sporadic hypertrophic
cardiomyopathy and no first-degree relatives are clinically or
genetically affected. However because there is only a 50%
chance that a given chromosome will be inherited by each
child, the probability ofa new mutation appearing in the subse-
quent generation is determined by the number of offspring.
Documentation ofgermline mutations is frequently difficult in
families of small size. Analyses ofthe H family demonstrated a
de novo 13 cardiac MHC gene mutation that is inherited; analy-
ses of generations I and II identify sporadic disease while stud-
ies of generations II and III demonstrate a familial pattern. We
conclude that de novo 13 cardiac MHC gene mutations can
cause sporadic hypertrophic cardiomyopathy; in at least some
instances, these new mutations contribute to the incidence of
familial hypertrophic cardiomyopathy.
The demonstration ofde novo germline mutations in the 13
cardiac MHC gene in individuals with sporadic disease is im-
portant in confirming that these mutations are directly respon-
sible for producing hypertrophic cardiomyopathy. In families
that coinherit hypertrophic cardiomyopathy and abnormali-
ties oftheMHC gene, the possibility exists that these abnormali-
ties are merely linked to an unknown gene that is itselfresponsi-
ble for the phenotype. The evidence against this, although very















Figure 3. Example ofSTR sequence polymorphism used to confirm paternity. Alleles were typed by PCR amplification of a dimeric STR present
in the APOC2 gene in 22 unrelated individuals and in family H members. The proband (II- 1) inherits allele 8 from her mother (1-2) and there-
fore must inherit allele 9 from her father. This allele is present in individual I- 1, and occurs in 10 of44 alleles present in the unrelated probands (P ) .
strong, is circumstantial: mutations have not been seen in un-
affected individuals; mutations segregate concordant with dis-
ease status in large families; mutations affect conserved amino
acid residues, frequently altering the charge (21 ). The evidence
in families H and AR of a normal gene in unaffected individ-
uals acquiring a de novo mutation in individuals who develop
sporadic hypertrophic cardiomyopathy cannot be explained by









Figure 4. Detection of the Arg723Cys mutation in members of family
AR by BcgI restriction enzyme digestion of PCR amplified cDNA.
The pedigree is shown above, with symbols as for Fig. 2. A 500 base-
pair ,B cardiac MHC cDNA is amplified as previously described, using
primers numbered 1925 and 2424 (21 ). Digestion of a product of
normal sequence generates fragments of 320 and 150 bp (arrows).
The sample from individual II- 1 contains these fragments but also
the 500 base-pair fragment (arrow), because the Arg723Cys mutation
abolishes the BcgI site on the affected chromosome. This mutation
is not present in any other family member.
Because of the difficulties in clinically defining sporadic
cases we are not able to determine the precise proportion of all
sporadic hypertrophic cardiomyopathy that is caused by de
novo mutations in the j3 cardiac MHC gene. The finding ofthe
two de novo mutations among the seven probands studied pro-
vides an estimate of the frequency of myosin mutations as a
cause sporadic hypertrophic cardiomyopathy. It appears that
mutations in other genes can cause sporadic hypertrophic car-
diomyopathy with an identical phenotype. It seems likely that
other loci, as yet unknown, that cause familial hypertrophic
cardiomyopathy will be candidates for de novo mutations that
cause sporadic hypertrophic cardiomyopathy.
Alternatively, sporadic cases may occur through etiologi-
cally distinct mechanisms. Somatic mutations in the fi cardiac
MHC gene occurring during embryogenesis that affect the
heart progenitor cells but not the germline might be a cause of
sporadic disease. Given that such somatic mutations would be
unlikely to be expressed in peripheral leukocytes, these would
not be detected by the techniques used in this study. Undefined
environmental factors might similarly cause a hypertrophic
phenotype and contribute to the incidence of sporadic disease.
The finding of de novo mutations in the j3 cardiac MHC
gene in individuals with sporadic hypertrophic cardiomyopa-
thy has clinical implications. A genetic diagnosis based on dem-
onstration of a myosin heavy chain mutation should assist in
difficult diagnoses. The problems of establishing the clinical
diagnosis in individual H 1-1 highlight this issue. Co-existing
heart disease, especially hypertension, commonly confounds
interpretation of clinical studies, and may prevent the diagno-
sis, or exclusion, of hypertrophic cardiomyopathy. The find-
ings presented here suggest that the benefits of molecular ge-
netic analysis of the ,3 cardiac MHC gene can be extended to a
proportion of cases of sporadic hypertrophic cardiomyopathy.
We have previously shown that particular mutations specifi-
cally influence survival in familial hypertrophic cardiomyopa-
thy, with nonconservative amino acid substitutions being asso-
ciated with a worse prognosis (21 ). In the absence of a family
history to predict prognosis, the value of defining the disease-
causing mutation as a prognostic indicator will be especially
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great in sporadic hypertrophic cardiomyopathy. Moreover, if
an individual was not clinically recognized as having sporadic
disease the impression of a benign family history may have led
to an inappropriate assumption of low risk status.
Genetic counseling for individuals with sporadic hypertro-
phic cardiomyopathy has not been previously feasible in the
absence of an understanding of the etiology of the condition.
On the assumption that sporadic disease was a separate, and
perhaps nongenetic entity, the risk oftransmission to offspring
may have been considered low. Whereas individuals with spo-
radic hypertrophic cardiomyopathy caused by de novo germ-
line mutations in the f# cardiac MHC gene will transmit the
disease gene to 50% of offspring. Once a f# cardiac MHC muta-
tion has been identified in a proband, with either sporadic or
familial hypertrophic cardiomyopathy, the possibility exists of
prenatal diagnosis or preclinical diagnosis in children.
We conclude that sporadic hypertrophic cardiomyopathy is
within the spectrum of familial disease. De novo f3 cardiac
MHC gene mutations in germline cells contribute to the inci-
dence of both the sporadic and familial variants of this dis-
order. Genetic analyses of sporadic cases of hypertrophic car-
diomyopathy can help to confirm diagnoses and provide im-
portant genetic information to physicians and affected
individuals.
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